Section 1 of 4Overview
Overview
An approved biologic fertility medicine standardized by FSH and LH activity; it is a mixture, not one chemically defined peptide.
Primary regulatory source
This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.
Section 2 of 4Identity and mechanism
Identity and mechanism
Its gonadotropin activity drives ovarian follicular development during assisted reproductive technology.
Menotropins is a biologic mixture standardized by FSH and LH activity; assigning one molecular formula or PubChem structure would be misleading.
Section 3 of 4Regulatory label facts
Regulatory label facts
FDA (United States; assisted reproductive technology).
The dose below reproduces a regulator-approved label; it is not a treatment recommendation. Menopur label: an individualized IVF protocol starting at 225 IU subcutaneously daily from cycle day 2 or 3, adjusted after 5 days; maximum 450 IU/day and 20 treatment days.
Section 4 of 4Safety boundary
Safety boundary
Ovarian hyperstimulation syndrome, thromboembolism, multiple gestation and pregnancy complications are major risks. Ultrasound and estradiol monitoring are integral, not optional extras.
This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.